Hunan Hansen Pharmaceutical Co., Ltd.

Equities

002412

CNE100000PK2

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 16/05/2024 BST 5-day change 1st Jan Change
6.03 CNY +0.50% Intraday chart for Hunan Hansen Pharmaceutical Co., Ltd. -1.47% -11.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hansen Pharmaceutical Gets Nod to Amend Information for Isoniazid Tablets MT
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Hansen Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on June 20, 2023 CI
Hunan Hansen Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022 CI
Hunan Hansen Pharmaceutical Co., Ltd. Announces Board Appointments CI
Hansen Pharma's Iohexol Injection Passes Drug Regulator's Evaluation MT
Hunan Hansen Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hansen Health Industry Co., Ltd. announced that it expects to receive CNY 40 million in funding from Hunan Hansen Pharmaceutical Co., Ltd. CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Hunan Hansen Pharmaceutical Co., Ltd. Approves Cash Dividend for 2020 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Hansen Health Industry Co., Ltd. announced that it expects to receive CNY 138 million in funding from Hunan Hansen Pharmaceutical Co., Ltd. CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Hunan Hansen Pharmaceutical Co., Ltd. Announces to Implement Final Cash Distribution Plan for 2019, Payable on 24 June 2020 CI
Chart Hunan Hansen Pharmaceutical Co., Ltd.
More charts
Hunan Hansen Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of traditional Chinese medicine preparations, chemical medicine and medical preparations. The Company’s main products include Simotang oral liquid, used for abdominal distention and phlegmatic abdominalgia; Yushangling capsules, used for injuries from falls; Yinxingye capsules, used for stroke and chest distress, as well as Suoquan capsules, used for kidney deficiency, among others. The Company mainly distributes its products in domestic markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002412 Stock
  4. News Hunan Hansen Pharmaceutical Co., Ltd.
  5. Hansen Pharmaceutical Gets Nod to Amend Information for Isoniazid Tablets